Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2023 Earnings Conference Call February 29, 2024 8:30 AM ET

Company Participants

Michael Kalb - Executive Vice President and Chief Financial Officer

Richard Daly - President and Chief Executive Officer

Jeffrey Del Carmen - Executive Vice President and Chief Commercial Officer

Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer

Gary Ingenito - Chief Medical and Regulatory Officer

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Joon Lee - Truist Securities

Joseph Catanzaro - Piper Sandler

Leland Gershell - Oppenheimer

Operator

Hello, and welcome to the Catalyst Pharmaceuticals Inc. Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to CFO, Mike Kalb. Please go ahead, Mike.

Michael Kalb

Thank you. Good morning, everyone and thank you for joining our conference call to discuss Catalyst's fourth quarter and full year 2023 financial results and business highlights. Leading the call today is Richard Daly, CEO. We are also joined by Dr. Steven Miller, our Chief Operating Officer and Chief Scientific Officer; and Jeffrey Del Carmen, our Chief Commercial Officer. Further for the Q&A session, Dr. Gary Ingenito, our Chief Medical and Regulatory Officer, will be available for questions.

Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of federal securities laws. These statements relate to our current expectations, estimates and projections and are not guarantees of future performance. They involve risks, uncertainties and assumptions that are difficult to predict and may prove not to be accurate. Actual results may vary from the expectations contained in our forward-looking statements. These forward-looking statements should be considered only in conjunction with the detailed information contained in our SEC filings, including the risk factors described in our 2023 annual report on Form 10-K.

At this time, I'll turn the call over to Rich.

Richard Daly

Thanks, Mike and welcome everyone to the call. First, I'd like to say that our entire team is proud of the work that we do on behalf of the orphan and rare disease communities that we serve, and we're especially excited to be speaking you to today on Rare Disease Day.